Use a maximum of two downloads here
As VP of Translational Science and Experimental Medicine (TSEM) for Respiratory and Immunology (R&I) at AstraZeneca, I am part of the R&I leadership team spanning the UK, Sweden and US. Emphasising the importance of understanding the heterogeneity of common chronic disease, I designed and launched TSEM to provide a translational roadmap to novel targets, biomarkers and patient subgroups, based on building a molecular understanding of disease pathology and biomarkers, with precision medicine from the start.
Already we have a number of molecules in clinical development where we are actively developing what will be some of the first examples of precision medicine for common chronic disease.
Previously, as Global Head of Genomics Portfolio in AstraZeneca’s Centre for Genomics Research, I played a pivotal role in securing the $400+ million investment to integrate genome sequence and clinical data from up to two million patients. Other business-critical deliveries have included AstraZeneca’s first respiratory diagnostic achieving EU CE-IVD certification in December 2018, and FDA clearance for a Point of Care (PoC) serum uric acid meter to monitor the effectiveness of urate lowering therapies.
I completed my PhD in molecular genetics at the University of Liverpool and I have published over 50 peer-reviewed articles, most recently in the New England Journal of Medicine, Nature and Nature Reviews Drug Discovery.
It is a privilege to have the opportunity to apply strong science with many of the talented scientists and teams at AstraZeneca to bring life changing medicines to improve patients’ lives.
Award
Award
Award
Award
Key Achievements
¶
Featured publications
Genetic architecture of telomere length in 462,666 UK Biobank whole-genome sequences.
Burren OS et al, Platt A, Vitsios D, Wu Q; AstraZeneca Genomics Initiative; Codd V, Nelson CP, Samani NJ, March RE, Wasilewski S, Carss K, Fabre M, Wang Q, Pangalos MN, Petrovski S. (2024) Nature Genetics 2024 Sep;56(9):1832-1840. doi: 10.1038/s41588-024-01884-7.
Rare variant associations with plasma protein levels in the UK Biobank.
Dhindsa RS, et al, Platt A et al, Petrovski, S. (2023) Nature. Oct;622(7982):339-347. doi: 10.1038/s41586-023-06547-x. Epub 2023 Oct 4. PMID: 37794183; PMCID: PMC10567546.
FinnGen provides genetic insights from a well-phenotyped isolated population.
Kurki MI, et al, Platt A, et al, Daly MJ, Palotie A. (2023) Nature. 613(7944):508-518. doi: 10.1038/s41586-022-05473-8.
Rare variant contribution to human disease in 281,104 UK Biobank exomes.
Wang, Q. et al. Platt, A., Haefliger, C., Petrovski, S. (2021) Nature, 597: 527–532 https://doi.org/10.1038/s41586-021-03855-y
Identification of a novel missense variant in SPDL1 associated with idiopathic pulmonary fibrosis.
Dhindsa, R. et al , Molyneaux , P., Platt, A.*, Petrovski, S. (2021) Commun. Biol., 4:392 doi: 10.1038/s42003-021-01910-y
*Joint senior author as stated in paper
Diagnostic utility of exome sequencing for kidney disease. New England Journal of Medicine.
Groopman, E. et al, Platt, A.*, Goldstein, D.B., Gharavi, A.G. (2019) Diagnostic utility of exome sequencing for kidney disease. New England Journal of Medicine, 380(2):142-151.doi: 10.1056/NEJMoa1806891
*Joint senior author as stated in paper
Drug development in the era of precision medicine.
Dugger S, Platt A, Goldstein D. (2018). Nature Reviews Drug Discovery. 17 (3):183-196. doi:10.1038/nrd.2017.226 Published online 8 Dec 2017
IL-6 Receptor Inhibition Positively Modulates Bone Balance in Rheumatoid Arthritis Patients with an Inadequate Response to Anti-Tumor Necrosis Factor Therapy: Biochemical Marker Analysis of Bone Metabolism in the tocilizumab RADIATE Study.
Karsdal, M. A., Schett, G., Emery, P., Harari, O., Byrjalsen, I., Kenwright, A., Bay-Jensen A. C., Platt, A. (2012) Semin Arthritis Rheum. 42(2):131-9
The yeast galactose genetic switch is mediated by formation of a Gal4p/Gal80p/Gal3p complex.
Platt, A. and Reece, R.J. (1998). EMBO. J. 17 (14): 4086-4091.
Veeva ID: Z4-73193
Date of preparation: April 2025